The U.S. FDA cleared four new molecular entities (NMEs) in the first two months of 2026, part of a 26‑approval run through February. The tally—eight approvals in January and 18 in February—keeps early‑year activity within historical ranges compared with 2025. Approvals include therapies for dermatitis and achondroplasia among others, reflecting continued regulatory throughput across multiple therapeutic areas. The agency’s output underscores steady momentum for new drugs despite an evolving biotech financing environment. Companies and investors will monitor whether this pace sustains as submissions and advisory actions unfold through the rest of the year.